KEY POINTS
• Emerging HSCs require Jak2 and Pi3k signaling for proliferation and survival
• Embryonic HSCs are unaffected by the JAK2V617F mutation
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ABSTRACT
The regulation of hematopoietic stem cell (HSC) emergence during development provides important information about the basic mechanisms of blood stem cell generation, expansion and migration. We set out to investigate the role that cytokine signaling pathways play in these early processes and show here that the two cytokines interleukin 3 and thrombopoietin have the ability to expand hematopoietic stem and progenitor numbers by regulating their survival and proliferation. For this, they differentially employ the Jak2 and Pi3k signaling pathways, with Jak2 mainly relaying the pro-proliferation signaling, while Pi3k mediates the survival signal.
Furthermore, using Jak2-deficient embryos, we demonstrate that Jak2 is crucially required for the function of the first HSCs, while progenitors are less dependent on Jak2. The JAK2V617F mutation, which renders JAK2 constitutively active and which has been linked to myeloproliferative neoplasms, was recently shown to compromise adult HSC function, negatively affecting their repopulation and self-renewal ability, partly through the accumulation of JAK2V617F-induced DNA damage. We report here that nascent HSCs are resistant to the JAK2V617F mutation and show no decrease in repopulation or self-renewal and no increase in DNA damage, even in the presence of two mutant copies. More importantly, this unique property of embryonic HSCs is stably maintained through at least one round of successive transplantations.
In summary, our dissection of cytokine signaling in embryonic HSCs has uncovered unique properties of these cells that are of clinical importance.
INTRODUCTION
Adult-repopulating hematopoietic stem cells (HSCs) are first detected at embryonic day (E) 10.5 in the mouse aorta-gonads-mesonephros (AGM) region, where they are thought to emerge from the ventral endothelium of the dorsal aorta [1] [2] [3] .
Relatively little is known about how this is mediated by the microenvironment and, more specifically, which soluble factors act on nascent HSCs to regulate their emergence, survival, expansion and migration 2 . Understanding these complex processes and applying this knowledge to the recreation of the right conditions in vitro to facilitate the de novo generation and expansion of HSCs, would be of immense clinical value.
For this reason, our group previously carried out gene expression screens that resulted in the identification of novel positive and negative regulators of emerging HSCs 4 . These included Igf2 4 , Dlk1 5 and catecholamines that are secreted from the co-developing sympathetic nervous system 6 . Additional soluble factors that have been shown by other groups to be important for HSC production in the AGM include Bmp4 7 , Interleukin 1 (Il1) 8 , Il3 9 , Hedgehog 10 , retinoic acid 11 and nitric oxide 12, 13 .
Discovering the sources of these factors also allows for identification of the cells that contribute to the developing HSC niche 2 . These supportive cells are polarized to the ventral side of the AGM, encompassing the area of the developing gut 10, 14 , and include mesenchymal cells underneath the aorta 7, 15 . Cells of the sympathetic nervous system were shown to be part of the niche 6 , and there may also be important signals derived from endothelial cells and hematopoietic cells that are in close contact with emerging HSCs. In fact, inflammatory response signals released from primitive innate immune cells were recently demonstrated to play an important role in regulating HSC production [16] [17] [18] [19] .
A functional annotation enrichment analysis of the differentially expressed genes identified in our previous expression screen 4 has shown that components of cytokine signaling pathways are enriched amongst the genes upregulated in the AGM at the peak of HSC production, thus prompting us to investigate whether cytokine signaling plays a role in AGM hematopoiesis. Amongst the cytokines tested, we found that Il3 and thrombopoietin (Thpo) enhanced hematopoietic progenitor (HP) and HSC production in the AGM and that this was mediated via the Jak-Stat and Pi3k signaling pathways. Furthermore, while these cytokine pathways are known to also regulate adult hematopoiesis, we demonstrate here that there are differences in the 
Colony-forming assays
Cells were plated in M3434 Methocult (Stem Cell Technologies) in triplicate at 20,000, 50,000 and 100,000 cells per plate. Colonies were scored and counted after 7 days.
Proliferation and apoptosis assays
To assess proliferation, 10 μM BrdU (BD, Oxford, UK) was added during the 
Repopulation assays
Cell preparations were injected intravenously into irradiated (9.5 Gy) recipients that differed in CD45 isoforms. After 4 months, donor contribution to the peripheral blood was analyzed by flow cytometry using CD45.1-PE and CD45.2-FITC (eBioscience). Mice with a donor cell contribution of ≥ 5% were considered to be positive for repopulation. Multilineage analysis was carried out with B220-APC, CD3-PacificBlue (both BD), Mac1-APC and Gr1-PacificBlue (both eBioscience).
Peripheral blood counts were performed on an ABC blood counter (Woodley, Bolton, UK).
Immunohistochemistry
Cryosections from paraformaldehyde-fixed embryos were stained with anti-CD34-biotin (BD), Stat5 (Santa Cruz, Heidelberg, Germany), Thpo-biotin (Peprotech) and Ki67 (Novacastra, Milton Keynes, UK), followed by anti-rabbit-Alexa555, anti- 
Data analysis
Data were analyzed with GraphPad Prism and statistical significance calculated using the Student's t-test, except for repopulation data which were assessed through the Mann Whitney test.
RESULTS

Il3 and Thpo promote hematopoietic progenitor cell production
In our previous expression screen we identified genes that are upregulated in the E11 dorsal aorta (E11WA), the middle region of the E11 dorsal aorta where HSCs are located (E11mAo) and in the HSC-enriched E11 Ly6A-GFP+ fraction (E11GFP) 4 . A functional enrichment analysis using the DAVID software indicated that components of cytokine signaling pathways were enriched in our data sets. These included the Il2, Il3, Il6, erythropoietin (Epo), Thpo, Stat3 and Erk1/Erk2 Mapk signaling pathways, and the components were Hras1, Id1, Id2, Id3, Jak1, Jak2, Thpo increased the total number of hematopoietic colonies by 2.6-fold at 10ng/ml ( Figure 2D ), only slightly less than Il3. Adding 50ng/ml did not result in a further increase, and 100ng/ml only gave an increase of 3-fold compared with the control. As was observed for Il3, Thpo mainly expanded CFU-GM and CFU-Mix colonies ( Figure 2E ), and it did not affect the total number of AGM cells ( Figure   2F ).
We also added Epo, Il2 and Il6 to AGM explant cultures, but saw no effect ( Figure 2G-I ).
Il3 and Thpo elicit pro-survival and pro-proliferation responses
To shed light on the mechanism, we determined the number of apoptotic and proliferating cells within AGM hematopoietic stem and progenitor cells (HSPCs, ckit+CD45+). Il3 at 50ng/ml produced an almost 10-fold increase in ckit+CD45+ cells, while the increase with the same concentration of Thpo amounted to 4.2-fold ( Figure 3A) . This is likely due to a significant decrease in early apoptotic cells ( Figure 3B ). In addition, we also detected an increase in BrdU+ proliferating HSPCs, which was significant for Thpo-treated cells, but just failed to reach significance (p=0.053) for Il3 addition ( Figure 3C ).
Il3 and Thpo promote HSC production in an additive manner
To establish whether these cytokines were also able to expand HSCs, longterm repopulation assays were performed. Il3 was previously reported to expand AGM HSCs 9 , while the effect of Thpo was unknown. Addition of 100ng/ml of Thpo to AGM explants resulted in 100% of the injected mice being repopulated, in contrast to one-third of recipients of control AGMs with a significantly higher donor contribution in the peripheral blood ( Figure 3D ). To determine if Il3 and Thpo can work additively, both cytokines were added at 10ng/ml alone or in combination.
Either cytokine on its own produced a slight increase from one-third to one-half of recipients being repopulated, whereas adding both cytokines resulted in 90% of repopulation ( Figure 3E ). Donor contribution was also higher in recipients of AGM cells pre-treated with both cytokines compared with recipients of control or Thpoonly cells. The enhanced repopulation achieved with both cytokines was multi-lineage ( Figure 3F ). While we cannot rule out that at least some of the effects of the cytokines may be mediated via responsive cells in the microenvironment, it is likely that Il3 and Thpo act directly on HSPCs since Il3 receptor expression was detected on phenotypic AGM HSPCs (CD34+ckit+) 9 and transcripts for the Thpo receptor Mpl were found in intra-aortic clusters 22 .
Within our dataset were three downstream target genes, Id1, Id2 and Id3
( Figure 1A ). These can be activated through a number of stimuli including bone morphogenic proteins via Smads, C/EBPβ, Τ cell receptor signaling via the Ras/MAPK pathway and cytokines (reviewed in 23 ). Id1 and Id3 are subject to transient expression during development following stimulation, while Id2 mRNA is found more ubiquitously. Id1 is essential for adult HSC maintenance 24, 25 and is a downstream target of Il3 and Jak2-Stat5 signaling 23, 26, 27 . Id2 and Id3 perform functions at later stages in hematopoiesis 28, 29 . All 3 are expressed in AGM HSPCs ( Figure 3G ). To determine whether AGM HSC expansion could be linked to one of these target genes, AGMs were cultured with no cytokine, Il3 or Thpo and HSCenriched populations (ckit+CD45+CD41intermediate 30, 31 ) analyzed for Id gene expression. Figure 3H shows that only Id1 is significantly upregulated by Il3 and Thpo, which suggests that Id1 may also be crucial for AGM HSC expansion and survival.
Jak2 and Pi3k signaling is required for hematopoietic progenitor production
We next investigated the downstream signaling pathways of Il3 and Thpo.
Components of the Jak-Stat and Mapk pathways were enriched in our dataset ( Figure   1A ). In addition, Il3 and Thpo are known to signal through the Pi3k pathway. We tested if inhibitors specific to these pathways can block the effects of Il3 and Thpo.
Inhibitor concentrations were chosen based on published IC 50 values and test experiments. Addition of a Mapk pathway inhibitor (U0126) had no effect on CFU-C numbers ( Figure 4A) , suggesting that the Mapk pathway is not essential for HSPC maintenance or expansion.
We next added a Jak2 inhibitor (TG101348) and noted that this decreased CFU-C output in the absence of cytokines, albeit without quite reaching significance ( Figure 4B) . Interestingly, it blocked Il3-mediated CFU-C expansion, but did not interfere with Thpo signaling. Furthermore, it only reduced the number of BrdU+
HSPCs in the presence of Il3 (Figure 4C,D) , while the number of live cells was unaffected ( Figure 4E ), suggesting that Jak2 mediates the pro-proliferation effect of
Il3, but not the pro-survival signal. The overall number of AGM cells did not change, ruling out general toxicity ( Figure 4F ).
Finally, we tested a Pi3k inhibitor (LY294002) and observed that it reduced HP production even in the absence of cytokines, pointing to an essential role in AGM hematopoiesis ( Figure 4G) . Furthermore, the inhibitor also abrogated HP expansion induced by Il3 and Thpo (Figure 4G,H) . Total AGM cell numbers were not significantly altered ( Figure 4I) . The Pi3k inhibitor did not interfere with the proproliferation effect of Il3 and Thpo ( Figure 4J) ; however, it significantly decreased the number of live cells and increased the number of pre-apoptotic cells, thus blocking Figure 4K) . Taken together, these observations suggest that Jak2 and Pi3k perform independent functions downstream of Il3 and Thpo. We therefore added both inhibitors together to the explant cultures. This dramatically reduced hematopoietic colony output in the presence and absence of cytokines ( Figure 4L) and also decreased the number of HSPCs (Figure 4M ) to an extent that it precluded further analysis. The strong effect of the two inhibitors together was still hematopoiesis-specific as total AGM cell numbers were not significantly altered ( Figure 4N) . The fact that inhibition of both pathways had such a profound effect even in the absence of exogenous cytokines suggests that there may be an endogenous source of Il3 and Thpo. Indeed, expression of Il3 in the AGM in the proximity of HSPCs has previously been reported 9 , and we detected patches of Thpo protein in the ventral sub-aortic mesenchyme (Supplemental Fig. 1A ).
Jak2 is essential for emerging HSCs
As we had seen a slight decrease in colony formation with the Jak2 inhibitor in the absence of cytokines ( Figure 4B ) and detected Stat5, the main target of Jak2 in hematopoietic cells, in endothelial cells of the aorta and in intra-aortic hematopoietic clusters ( Figure 5A ) we decided to further investigate if Jak2 is required for AGM hematopoiesis.
We used Jak2-deficient mice, in which a mutant version of human JAK2, JAK2V617F, is knocked into the mouse Jak2 locus, creating a null allele 20 . Human JAK2V617F is not expressed as this requires the presence of Cre recombinase. Thus, the genotypes Jak2 +/fl and Jak2 fl/fl represent heterozygous and homozygous knockout mice, respectively. We first tested the ability of uncultured Jak2-deficient AGMs to form hematopoietic colonies and observed that colony formation was only slightly reduced ( Figure 5B) . We next transplanted uncultured Jak2-deficient AGMs.
Strikingly, removal of one or both copies of Jak2 dramatically decreased the number of repopulated mice and overall repopulation levels, demonstrating that Jak2 is essential for HSC production and/or maintenance in the AGM ( Figure 5C ). To investigate this further, we stained sections from E11.5 embryos with antibodies against CD34 and Ki67 to reveal hematopoietic clusters and proliferating cells, respectively. We also performed TUNEL assays to detect apoptotic cells ( Figure 5D ).
The results indicate that HSPC formation proceeds normally in the absence of Jak2, as hematopoietic clusters were still detected in Jak2 fl/fl embryos (white arrowheads in 
AGM HSCs are resistant to the effects of the JAK2V617F mutation
The JAK2V617F mutation is detected in the majority of patients with myeloproliferative neoplasms 32 and creates a constitutively active JAK2 kinase. The effect of the JAK2V617F mutation on HSCs has been studied 20,21,33-37 and was shown to compromise HSC function in one model 20, 34 , a defect that is even more severe when homozygous 21 . Using the model, in which JAK2V617F is expressed from the mouse endogenous Jak2 locus following recombination with Stella-Cre
21
, we set out to determine how constitutively active JAK2 would affect embryonic HSPCs.
Expression of one copy of JAK2V617F did not affect AGM HP numbers, while the homozygous JAK2V617F AGMs showed a slight reduction in colony output ( Figure   6A ). Contrary to the results obtained with adult HSCs 20, 21, 34 , similar percentages of mice were repopulated with wild-type (Jak2 +/+ ; 43%), heterozygous (Jak2
and homozygous (Jak2
VF/VF
; 38%) AGMs, and the overall repopulation levels in the peripheral blood were not significantly different ( Figure 6B) . Similarly, expression of
Id gene transcript was comparable between wild-type and Jak2 VF/VF AGM HSPCs ( Figure 3G ). Due to an impairment of self-renewal in adult JAK2V617F-expressing HSCs, secondary transplantations gave rise to markedly reduced repopulation 20, 34 .
It was thus striking to see that BM cells from primary recipients of homozygous AGM cells performed just as well in secondary repopulation assays as BM cells from primary recipients of wild-type AGM cells (Figure 6C). These results not only
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It has been reported that JAK2V617F-expressing adult HSCs are prone to enhanced lineage bias 34 and may in some cases show poor myeloid engraftment 21 .
Multilineage analysis of primary or secondary recipients of wild-type or JAK2V617F-expressing AGM HSCs revealed no obvious differences (Figure 6D,E) .
Transplantability of JAK2V617F-associated disease has been demonstrated 20, 21, 35 ; however, no changes in platelets, hematocrit, hemoglobin or white blood cell counts were observed in recipients of heterozygous or homozygous AGMs, even when repopulated at high levels, demonstrating that embryonic HSCs do not initiate a myeloproliferative disease (Figure 6F-I) .
The presence of the JAK2V617F mutation leads to increased DNA damage in HSCs, as measured by a ~4fold increase in γ-H2A.X foci 34, 35 , which may partly explain their compromised function. We investigated whether AGM HSCs are more resistant to JAK2V617F-induced DNA damage to explain their resilience to the presence of this mutation. Indeed, even after having undergone serial transplantation, AGM-derived HSCs homozygous for JAK2V617F did not accumulate any more γ-H2A.X-positive foci than their wild-type counterparts ( Figure 6J ).
We reasoned that the difference in sensitivity to the JAK2V617F mutation may be due to AGM HSCs expressing a different set of Jak-Stat signaling components. We, therefore, analyzed Jak-Stat pathway-related gene expression in sorted wild-type AGM and BM HSCs using the Qiagen Jak-Stat signaling pathway array. Figure 6K summarizes the genes that were found to be differentially expressed.
Socs3 stands out as an obvious candidate as it was shown to inhibit JAK2V617F 38 and its promoter displays hypermethylation in some patients with myeloproliferative neoplasms 39, 40 . It will be our main target for future mechanistic studies. Our inhibitor studies demonstrate that the Pi3k pathway is crucially important for AGM hematopoiesis and for relaying the Il3 and Thpo signal, while Jak2 only appears to be required for Il3 signaling. AGM hematopoiesis is almost completely abrogated when Jak2 and Pi3k are blocked simultaneously.
We also analyzed AGM hematopoiesis in Jak2 knockout mice. As had been observed in the inhibitor studies, HPs were only mildly affected by the absence of Jak2. At this stage of development, most of the progenitors found in uncultured AGMs are still yolk sac-derived and will not have been the product of HSC differentiation. This suggests that Jak2 is largely dispensable for yolk sac hematopoiesis. Recently, an essential role for Jak2 in adult HSC maintenance and self-renewal has been demonstrated 43, 44 . We now show that Jak2 is also crucially required for the function of the first HSCs that emerge in the AGM. Their generation and survival appear normal; however, they are compromised in their repopulation and self-renewal ability.
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We also investigated what impact an overactive Jak2 kinase would have on AGM HSPCs. The V617F mutation in the human JAK2 protein results in a constitutively active kinase that has been associated with the development of myeloproliferative neoplasm. Several genetic mouse models have been generated 20, 37, [45] [46] [47] [48] [49] , some of which have addressed the impact of the mutation on adult HSCs. Furthermore, the resilience to the effects of JAK2V617F is maintained in secondary transplantations, at which point adult JAK2V617F-expressing HSCs have almost become exhausted 20, 34 . This suggests that embryonic HSCs maintain at least part of their unique properties during the 4 months they reside in the adult BM niche prior to the secondary transplantation. AGM HSCs were also resistant to JAK2V617F-induced DNA damage. It will be interesting to see if this is a general property of embryonic HSCs or specific to JAK2V617F-induced DNA damage.
In an attempt to decipher how AGM HSCs escape the damaging effects of constitutively active Jak2, we determined whether any Jak-Stat signaling components are differentially expressed in AGM HSCs vs. adult BM HSCs. Of the 6 differentially expressed genes, Socs3 stands out as a potential candidate since, together with Socs1 it is considered to be the most potent inhibitor of cytokine signaling. Unlike other Socs family members, Socs1 and Socs3 can directly inhibit the catalytic activity of Jak via a KIR motif that is unique to these two proteins (reviewed in 50 ) . Importantly, it was demonstrated by in vitro assays that wild-type and mutant JAK2 are equally inhibited by SOCS3
38
; however, additionally processes such as promoter
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We also found Stat3 to be expressed at higher levels in AGM HSCs.
Interestingly, a Stat3-deficient background was reported to enhance Jak2V617F-associated disease in a mouse model 52 . An upregulation of Stat3 may therefore make AGM HSCs more resilient to the effects of JAK2V617F. Furthermore, Stat3 was also shown to be required for the induction of Socs3 52 , suggesting that higher levels of Stat3 result in upregulation of Socs3. It will be important to investigate these differences between embryonic and adult HSCs as these are not only relevant to human diseases, but may also allow for the exploitation of the unique properties of embryonic HSCs, such as proliferation without exhaustion and resistance to DNA damage, for adult HSC manipulation. 
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